What is the evidence for the use of NOACs in the setting of cardioversion?
Evidence is available for all 4 currently available NOACs: dabigatran, apixaban, rivaroxaban, and edoxaban. An existing systematic review from Renda et al239 compared the use of NOAC vs VKA in the setting of cardioversion in 6 studies.